tremelimumab,durvalumab
astrazeneca
tremelimumab/durvalumab produces favorable os benefit in unresectable hcc irrespective of albi grade #wcgic2022 #oncology 
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.